GS Cell Files Patent for CAR-NK Immune Cell Therapy Targeting Solid Tumors
CAR-NK Patent Incorporates CLDN18.2 Antibody into GS Cell's Immune Cell Platform
Next-Generation Immunotherapy Technology Targets Solid Tumors Such as Gastric and Pancreatic Cancer
GS Cell announced on March 31 that it has filed a patent related to immune cell therapy targeting solid tumors.
This patent is for a pipeline developed to target CLDN18.2, based on GS Cell's CAR-NK platform. It is an example of expanding the applicability to the field of solid tumors. CLDN18.2 is a protein expressed in various solid tumors such as gastric cancer, pancreatic cancer, and esophageal cancer, and has recently emerged as a major therapeutic target in the global pharmaceutical and biotech industries.
Unlike CAR-T therapies, which utilize the patient's own cells, CAR-NK therapies use cells from healthy donors. This enables the development of an off-the-shelf treatment that can be mass produced.
The innate immune characteristics of NK cells are expected to offer a high level of safety. From the perspectives of manufacturing and supply, this approach is seen as an alternative that can help reduce treatment costs and improve patient accessibility through greater efficiency.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seongyong Won, CEO of GS Cell, stated, "This patent represents one of the ongoing achievements in the research and development of solid tumor pipelines based on our CAR-NK platform. Through continued R&D, we will further strengthen our global competitiveness."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.